By September 30, the BioCentury 100 index had tumbled 40% from its all-time high in July, down 3% from the start of the year. Funding remained sturdy, however, with biotechs raising $36.1 billion (excluding partnership monies) and debt offerings up to $24.8 billion, thanks to $5 billion-plus deals by Biogen, Celgene and Gilead. 15 companies raised $1.8 billion in public floatations and follow-on offerings were a healthy $5.4 billion. Money raised by private companies also jumped to $3.2 billion, led by a $320-million series A by Immunocore.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. 3Q15—biotech in the balance. Nat Biotechnol 33, 1127 (2015). https://doi.org/10.1038/nbt.3407
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3407
